Search

Your search keyword '"Jemaa, Riadh"' showing total 228 results
Start Over Author "Jemaa, Riadh"
228 results on '"Jemaa, Riadh"'

1. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)

Author

Manfredi Rizzo, Alessandro Colletti, Peter E. Penson, Niki Katsiki, Dimitri P. Mikhailidis, Peter P. Toth, Ioanna Gouni-Berthold, John Mancini, David Marais, Patrick Moriarty, Massimiliano Ruscica, Amirhossein Sahebkar, Dragos Vinereanu, Arrigo Francesco Giuseppe Cicero, Maciej Banach, Julio Acosta, Mutaz Al-Khnifsawi, Fahad Alnouri, Fahma Amar, Atanas G. Atanasov, Gani Bajraktari, Sonu Bhaskar, Agata Bielecka-Dąbrowa, Bojko Bjelakovic, Eric Bruckert, Ibadete Bytyçi, Alberto Cafferata, Richard Ceska, Arrigo F.G. Cicero, Krzysztof Chlebus, Xavier Collet, Magdalena Daccord, Olivier Descamps, Dragan Djuric, Ronen Durst, Marat V. Ezhov, Zlatko Fras, Dan Gaita, Adrian V. Hernandez, Steven R. Jones, Jacek Jozwiak, Nona Kakauridze, Amani Kallel, Amit Khera, Karam Kostner, Raimondas Kubilius, Gustavs Latkovskis, G.B. John Mancini, A. David Marais, Seth S. Martin, Julio Acosta Martinez, Mohsen Mazidi, Erkin Mirrakhimov, Andre R. Miserez, Olena Mitchenko, Natalya P. Mitkovskaya, Patrick M. Moriarty, Seyed Mohammad Nabavi, Devaki Nair, Demosthenes B. Panagiotakos, György Paragh, Daniel Pella, Zaneta Petrulioniene, Matteo Pirro, Arman Postadzhiyan, Raman Puri, Ashraf Reda, Željko Reiner, Dina Radenkovic, Michał Rakowski, Jemaa Riadh, Dimitri Richter, Maria-Corina Serban, Abdullah M.A Shehab, Aleksandr B. Shek, Cesare R. Sirtori, Claudia Stefanutti, Tomasz Tomasik, Margus Viigimaa, Pedro Valdivielso, Branislav Vohnout, Stephan von Haehling, Michal Vrablik, Nathan D. Wong, Hung-I Yeh, Jiang Zhisheng, and Andreas Zirlik

Subjects
NAFLD, Nutraceuticals, Dietary supplements, Liver steatosis, Position paper, Therapeutics. Pharmacology, RM1-950
Abstract

Non-Alcoholic Fatty Liver Disease (NAFLD) is a common condition affecting around 10–25% of the general adult population, 15% of children, and even > 50% of individuals who have type 2 diabetes mellitus. It is a major cause of liver-related morbidity, and cardiovascular (CV) mortality is a common cause of death. In addition to being the initial step of irreversible alterations of the liver parenchyma causing cirrhosis, about 1/6 of those who develop NASH are at risk also developing CV disease (CVD). More recently the acronym MAFLD (Metabolic Associated Fatty Liver Disease) has been preferred by many European and US specialists, providing a clearer message on the metabolic etiology of the disease.The suggestions for the management of NAFLD are like those recommended by guidelines for CVD prevention. In this context, the general approach is to prescribe physical activity and dietary changes the effect weight loss. Lifestyle change in the NAFLD patient has been supplemented in some by the use of nutraceuticals, but the evidence based for these remains uncertain. The aim of this Position Paper was to summarize the clinical evidence relating to the effect of nutraceuticals on NAFLD-related parameters. Our reading of the data is that whilst many nutraceuticals have been studied in relation to NAFLD, none have sufficient evidence to recommend their routine use; robust trials are required to appropriately address efficacy and safety.

Published
2023
Full Text
View/download PDF

9. Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases - A position paper from the International Lipid Expert Panel (ILEP)

Author

Massimiliano Ruscica, Peter E. Penson, Nicola Ferri, Cesare R. Sirtori, Matteo Pirro, G.B. John Mancini, Naveed Sattar, Peter P. Toth, Amirhossein Sahebkar, Carl J. Lavie, Nathan D. Wong, Maciej Banach, Julio Acosta, Mutaz Al-Khnifsawi, Fahad Alnouri, Fahma Amar, Atanas G. Atanasov, Gani Bajraktari, Sonu Bhaskar, Bojko Bjelakovic, Eric Bruckert, Richard Ceska, Arrigo F.G. Cicero, Xavier Collet, Olivier Descamps, Dragan Djuric, Ronen Durst, Marat V. Ezhov, Zlatko Fras, Dan Gaita, Adrian V. Hernandez, Steven R. Jones, Jacek Jozwiak, Nona Kakauridze, Amani Kallel, Niki Katsiki, Amit Khera, Karam Kostner, Raimondas Kubilius, Gustavs Latkovskis, A. David Marais, Seth S. Martin, Julio Acosta Martinez, Mohsen Mazidi, Dimitri P. Mikhailidis, Erkin Mirrakhimov, Andre R. Miserez, Olena Mitchenko, Natalya P. Mitkovskaya, Patrick M. Moriarty, Seyed Mohammad Nabavi, Devaki Nair, Demosthenes B. Panagiotakos, György Paragh, Daniel Pella, Zaneta Petrulioniene, Arman Postadzhiyan, Raman Puri, Ashraf Reda, Željko Reiner, Dina Radenkovic, Michał Rakowski, Jemaa Riadh, Dimitri Richter, Manfredi Rizzo, Maria-Corina Serban, Abdulla M.A. Shehab, Aleksandr B. Shek, Claudia Stefanutti, Tomasz Tomasik, Margus Viigimaa, Pedro Valdivielso, Dragos Vinereanu, Branislav Vohnout, Stephan von Haehling, Michal Vrablik, Hung-I Yeh, Jiang Zhisheng, Andreas Zirlik, Ruscica M, Penson PE, Ferri N, Sirtori CR, Pirro M, Mancini GBJ, Sattar N, Toth PP, Sahebkar A, Lavie CJ, Wong ND, Banach M, International Lipid Expert Panel (ILEP) and International Lipid Expert Panel Experts, Cicero AFG, Ruscica M., Penson P.E., Ferri N., Sirtori C.R., Pirro M., Mancini G.B.J., Sattar N., Toth P.P., Sahebkar A., Lavie C.J., Wong N.D., Banach M., Acosta J., Al-Khnifsawi M., Alnouri F., Amar F., Atanasov A.G., Bajraktari G., Bhaskar S., Bjelakovic B., Bruckert E., Ceska R., Cicero A.F.G., Collet X., Descamps O., Djuric D., Durst R., Ezhov M.V., Fras Z., Gaita D., Hernandez A.V., Jones S.R., Jozwiak J., Kakauridze N., Kallel A., Katsiki N., Khera A., Kostner K., Kubilius R., Latkovskis G., Marais A.D., Martin S.S., Martinez J.A., Mazidi M., Mikhailidis D.P., Mirrakhimov E., Miserez A.R., Mitchenko O., Mitkovskaya N.P., Moriarty P.M., Nabavi S.M., Nair D., Panagiotakos D.B., Paragh G., Pella D., Petrulioniene Z., Postadzhiyan A., Puri R., Reda A., Reiner Z., Radenkovic D., Rakowski M., Riadh J., Richter D., Rizzo M., Serban M.-C., Shehab A.M.A., Shek A.B., Stefanutti C., Tomasik T., Viigimaa M., Valdivielso P., Vinereanu D., Vohnout B., von Haehling S., Vrablik M., Yeh H.-I., Zhisheng J., Zirlik A., and UCL - (SLuc) Service de pathologie cardiovasculaire

Subjects
RM, Arterial disease, Anti-Inflammatory Agents, Inflammation, Disease, C-reactive protein, cardiovascular disease, inflammation, nutraceuticals, omega-3, position paper, red-yeast rice, 030204 cardiovascular system & hematology, Bioinformatics, Systemic inflammation, 03 medical and health sciences, 0302 clinical medicine, Nutraceutical, Medicine, Humans, Position paper, 030212 general & internal medicine, Uncategorized, Omega-3, biology, Cardiovascular disease, Nutraceuticals, Red-yeast rice, Biomarkers, Cardiovascular Diseases, Lipids, Dietary Supplements, Vascular inflammation, business.industry, C-reactive protein, Cardiovascular disease, Inflammation, Nutraceuticals, Omega-3, Position paper, Red-yeast rice, Anti-Inflammatory Agents, Biomarkers, Cardiovascular Diseases, Humans, Inflammation, Lipids, Dietary Supplements, biology.protein, medicine.symptom, Cardiology and Cardiovascular Medicine, business
Abstract

Inflammation is a marker of arterial disease stemming from cholesterol-dependent to -independent molecular mechanisms. In recent years, the role of inflammation in atherogenesis has been underpinned by pharmacological approaches targeting systemic inflammation that have led to a significant reduction in cardiovascular disease (CVD) risk. Although the use of nutraceuticals to prevent CVD has largely focused on lipid-lowering (e.g, red-yeast rice and omega-3 fatty acids), there is growing interest and need, especially now in the time of coronavirus pandemic, in the use of nutraceuticals to reduce inflammatory markers, and potentially the inflammatory CVD burden, however, there is still not enough evidence to confirm this. Indeed, diet is an important lifestyle determinant of health and can influence both systemic and vascular inflammation, to varying extents, according to the individual nutraceutical constituents. Thus, the aim of this Position Paper is to provide the first attempt at recommendations on the use of nutraceuticals with effective anti-inflammatory properties.

Published
2021

16. Statin therapy in athletes and patients performing regular intense exercise - Position paper from the International Lipid Expert Panel (ILEP)

Author

Niki Katsiki, Dimitri P. Mikhailidis, Gani Bajraktari, Andre R. Miserez, Arrigo F.G. Cicero, Eric Bruckert, Maria-Corina Serban, Erkin Mirrakhimov, Fahad Alnouri, Željko Reiner, György Paragh, Amirhossein Sahebkar, Maciej Banach, Fahma Amar, Atanas G. Atanasov, Marcin A. Bartlomiejczyk, Bojko Bjelakovic, Agata Bielecka-Dabrowa, Alberto Cafferata, Richard Ceska, Xavier Collet, Olivier Descamps, Nair Devaki, Dragan Djuric, Ronen Durst, Marat V. Ezhov, Zlatko Fras, Dan Gaita, Stephan von Haehling, Adrian V. Hernandez, Steven R. Jones, Jacek Jozwiak, Nona Kakauridze, Amit Khera, Karam Kostner, Raimondas Kubilius, Gustavs Latkovskis, G.B. John Mancini, A. David Marais, Seth S. Martin, Julio Acosta Martinez, Mohsen Mazidi, Olena Mitchenko, Patrick Moriarty, Seyed Mohammad Nabavi, Demosthenes B. Panagiotakos, Daniel Pella, Peter E. Penson, Zaneta Petrulioniene, Matteo Pirro, Arman Postadzhiyan, Raman Puri, Ashraf Reda, Jemaa Riadh, Dimitri Richter, Manfredi Rizzo, Massimiliano Ruscica, Naveed Sattar, Abdulla M.A. Shehab, Aleksandr B. Shek, Cesare R. Sirtori, Claudia Stefanutti, Tomasz Tomasik, Peter P. Toth, Margus Viigimaa, Dragos Vinereanu, Branislav Vohnout, Michal Vrablik, Nathan D. Wong, Hung-I Yeh, Jiang Zhisheng, Andreas Zirlik, and Katsiki N, Mikhailidis DP, Bajraktari G, Miserez AR, Cicero AFG, Bruckert E, Serban MC, Mirrakhimov E, Alnouri F, Reiner Ž, Paragh G, Sahebkar A, Banach M

Subjects
0301 basic medicine, medicine.medical_specialty, Consensus, Sports medicine, Context (language use), Physical exercise, 03 medical and health sciences, 0302 clinical medicine, Athleths, Muscular Diseases, Statin intolerance, Medicine, Humans, Adverse effect, Athleth, Exercise, Mylagia, Dyslipidemias, Pharmacology, biology, business.industry, Athletes, Exercises, Athleths, Exercises, Management, Mylagia, Statin intolerance, Management, medicine.disease, biology.organism_classification, 030104 developmental biology, 030220 oncology & carcinogenesis, Physical therapy, Position paper, Statin therapy, Hydroxymethylglutaryl-CoA Reductase Inhibitors, business, Dyslipidemia
Abstract

Acute and chronic physical exercises may enhance the development of statin-related myopathy. In this context, the recent (2019) guidelines of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) for the management of dyslipidemias recommend that, although individuals with dyslipidemia should be advised to engage in regular moderate physical exercise (for at least 30 min daily), physicians should be alerted with regard to myopathy and creatine kinase (CK) elevation in statin-treated sport athletes. However it is worth emphasizing that abovementioned guidelines, previous and recent ESC/EAS consensus papers on adverse effects of statin therapy as well as other previous attempts on this issue, including the ones from the International Lipid Expert Panel (ILEP), give only general recommendations on how to manage patients requiring statin therapy on regular exercises. Therefore, these guidelines in the form of the Position Paper are the first such an attempt to summary existing, often scarce knowledge, and to present this important issue in the form of step-by-step practical recommendations. It is critically important as we might observe more and more individuals on regular exercises/athletes requiring statin therapy due to their cardiovascular risk.

Published
2020

23. Association of MTHFR C677T, MTHFR A1298C, and MTRR A66G Polymorphisms with Neural Tube Defects in Tunisian Parents

Author

Nasri, Kaouther, primary, Midani, Fatma, additional, Kallel, Amani, additional, Ben Jemaa, Nadia, additional, Aloui, Mariem, additional, Boulares, Miryam, additional, Lassoued, Mehdi, additional, Ben Halima, Meriam, additional, Ben Wafi, Safa, additional, Soussi, Mariem, additional, Mahjoubi, Imen, additional, Baara, Abir, additional, Ben Fradj, Mohamed Kacem, additional, Omar, Souhail, additional, Feki, Moncef, additional, Jemaa, Riadh, additional, Gaigi, Soumeya Siala, additional, and Marrakchi, Raja, additional

Published
2019
Full Text
View/download PDF

28. Association of FokI polymorphism of vitamin D receptor with urothelial bladder cancer in Tunisians: role of tobacco smoking and plasma vitamin D concentration

Author

Jemaa Riadh, Moncef Feki, Ahmed Sallemi, Naziha Kaabachi, Mohamed Kacem Ben Fradj, Sami Ben Rhouma, Yassine Nouira, Mohamed Mourad Gargouri, Mohamed Ali Ben Chehida, Yassine Ouanes, and Amani Kallel

Subjects
0301 basic medicine, Male, medicine.medical_specialty, Tunisia, Genotype, Biology, Calcitriol receptor, vitamin D deficiency, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Vitamin D and neurology, medicine, Odds Ratio, Humans, Genetic Predisposition to Disease, Neoplasm Invasiveness, Vitamin D, Allele frequency, Alleles, Genetic Association Studies, Aged, Neoplasm Staging, Smoking, Case-control study, General Medicine, Odds ratio, Middle Aged, medicine.disease, FokI, 030104 developmental biology, Endocrinology, Urinary Bladder Neoplasms, 030220 oncology & carcinogenesis, Case-Control Studies, biology.protein, Receptors, Calcitriol, Female, Polymorphism, Restriction Fragment Length
Abstract

The aim of the study was to test whether the VDR FokI polymorphism is associated with the risk of urothelial bladder cancer (UBC) in Tunisians. The study included 200 unrelated patients with UBC and 200 healthy controls. Genotyping of the VDR FokI polymorphism was determined by PCR-RFLP method. Plasma 25-hydroxyvitamin D concentrations were measured by immunoassay. Binary logistic regression model was applied to test how the association of VDR FokI polymorphism is independent of potential confounding factors. Genotype distribution (FF, 45 vs. 55 %; Ff, 52.1 vs. 47.9 %, and ff, 12 vs. 5.5 %, respectively) and allele frequencies (F, 66.5 vs. 74.8 % and f, 33.5 vs. 25.2 %, respectively) were significantly different between UBC patients and controls. The "ff" genotype [OR (95 % CI), 2.66 (1.24-5.73); p = 0.012] and "f" allele [1.49 (1.09-2.02); p = 0.010] were associated with increased risk of UBC. The association remained significant in multivariate analysis. Stratified analyses showed that VDR FokI polymorphism is only associated with UBC risk in ever-smokers, subjects exposed to chemical carcinogens and those with plasma 25-hydroxyvitamin D over 12 μg/L. The "f" allele of VDR FokI polymorphism is associated with a higher risk of UBC in Tunisians, especially in smokers as well as subjects with occupational exposition and subjects without vitamin D deficiency. These results should be replicated in other ethnic groups and the influence of other genetic factors and environments on this association should be investigated.

Published
2015

29. Association between paraoxonase-1 gene promoter -108C/T polymorphism and myocardial infarction in the Tunisian male population / Tunuslu erkek populasyonunda miyokard enfarktüs ile paraoksonaz -1 gen başlatıcı -108C/T polimorfizmi arasındaki ilişki

Author

Sbai, Mohamed Hédi, primary, Kallel, Amani, additional, Sediri, Yousra, additional, Lassoued, Mehdi, additional, Feki, Moncef, additional, Mourali, Mohamed Sami, additional, Kaabachi, Naziha, additional, and Jemaa, Riadh, additional

Published
2016
Full Text
View/download PDF

31. 0185: Prevalence of conventional risk factors in 44154 Tunisians patients with coronary heart disease

Author

Jemaa, Riadh, primary, Kallel, Amani, additional, Sbaï, Mohamed Hédi, additional, Rabie, Razgallah, additional, Kafsi, Mohamed Naceur, additional, Zaouali, R.M, additional, Mechmeche, Rachid, additional, Haouala, Habib, additional, Slimane, M.L, additional, Belhani, A., additional, Ben Khalfallah, A., additional, Gamra, H., additional, Maatouk, F., additional, Ammar, H., additional, Chaouech, A., additional, Boughzala, E., additional, Bouajina, A., additional, and Chehaibi, N., additional

Published
2016
Full Text
View/download PDF

40. Angiotensin II Receptor Gene A1166C Variant and Hypertension in Tunisian Population

Author

Soualmia, Hayet, Ayadi, Ilhem, Kallel, Amani, Jemaa, Riadh, Feki, Moncef, Sanhaji, Haifa, Kaabachi, Naziha, Soualmia, Hayet, Ayadi, Ilhem, Kallel, Amani, Jemaa, Riadh, Feki, Moncef, Sanhaji, Haifa, and Kaabachi, Naziha

Abstract

Many genes have been proposed as candidate genes for hypertension. Among these genes, the angiotensin II type 1 receptor gene (AGTR1) has been investigated in the pathogenesis of hypertension, but studies have often generated controversial results. In this study, we analyzed the relationship between the A1166C variant of the AGTR1 and hypertension in a sample from the Tunisian population. Analysis of the AGTR1 genotypes was performed in 388 Tunisian patients with hypertension and 428 healthy subjects by polymerase chain reaction-restriction fragment length polymorphism. The results shows that the AGTR1 genotypes distribution and allele frequencies were not significantly different between the hypertensive and normotensive subjects (p>0.05). This polymorphism was not associated with hypertension (OR = 1.03, 95% CI [0.47-2.24]; p = 0.58) for AC and (OR = 1.19, 95% CI [0.65-2.19]; p = 0.83) for CC in comparison to the AA wild homozygous. After adjustment for the confounding factors of age, gender, body mass index, fasting glucose concentration, dyslipidemia and smoking, the OR for hypertension remained no significant (OR = 1.28, 95% CI [0.87-1.84]; p = 0.50) for CC vs AA. Furthermore, no relationship was found between clinical characteristics and AGTR1 genotypes. In the conclusion; our data suggested that the A1166C variant of the AGTR1 is not involved in the pathogenesis of hypertension in the Tunisian population.

Published
2014

41. ScaI Atrial Natriuretic Peptide Gene Polymorphism and Hypertension in the Tunisian Population

Author

Soualmia, Hayet, Ayadi, Ilhem, Kallel, Amani, Midani, Fatma, Jemaa, Riadh, Feki, Moncef, Sanhaji, Haifa, Kaabachi, Naziha, Soualmia, Hayet, Ayadi, Ilhem, Kallel, Amani, Midani, Fatma, Jemaa, Riadh, Feki, Moncef, Sanhaji, Haifa, and Kaabachi, Naziha

Abstract

Numerous genetic variants have been linked to hypertension. Among these variants T2238C polymorphism in atrial natriuretic peptide gene has been investigated in the pathogeneses of hypertension, but studies have often generated controversial results. The aim of this study was to investigate the association between hypertension and the ANP/ T2238C variant gene that led to the loss of ScaI restriction site, thus eliminated the regular stop codon and involved an extension of the human ANP by two additional arginines. We genotyped 384 patients with hypertension and 435 healthy controls. The ScaI ANP gene polymorphism was determined by polymerase chain reaction-restriction fragment length polymorphism analysis. The results shows that the ScaI ANP gene polymorphism genotypes distribution and allele frequencies were not significantly different between the hypertensive and normotensive subjects (p>0.05). The frequencies of A2 wild allele and A1 mutant allele were 48% and 52% respectively in hypertensive patients and 49% and 51% in control group (p=0.66). This polymorphism is not associated with hypertension (OR= 1.55, 95% CI [0.82-2.92]; p=0.17) for TC and (OR=1.80, 95% CI [0.81-3.98]; p=0.14) for CC after adjustment for age, gender, body mass index, fasting glucose concentration, dyslipidemia and smoking. Furthermore, no relationship was found between clinical characteristics and ScaI ANP genotypes. As a conclusion; this study suggested that the ScaI ANP gene polymorphism is not associated with hypertension in the Tunisian population.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results